Copyright
©The Author(s) 2022.
World J Virol. Sep 25, 2022; 11(5): 221-236
Published online Sep 25, 2022. doi: 10.5501/wjv.v11.i5.221
Published online Sep 25, 2022. doi: 10.5501/wjv.v11.i5.221
Table 1 Approved vaccines that have received the attention of the scientific community concerning coronavirus disease 2019 as potential prototypes for developing mucosal coronavirus disease 2019 vaccines
| Name of vaccine | Form | Immunity | Dosage | Route |
| OPV (oral poliovirus vaccine) | Live attenuated poliovirus (Sabin strain types 1, 2 or 3) | Poliovirus-specific mucosal immunity | 2 doses | Oral |
| BCG (Bacille Calmette-Guerin) | Live attenuated bacteria Mycobacterium bovis | Mycobacterium-specific mucosal and systemic immunity | 0.05 mL until 1 yr of age; 0.1 mL thereafter | Intradermal injection subcutaneous |
| MMR (measles, mumps and rubella vaccines) | Weakened forms of the measles, mumps and rubella viruses | Measles, mumps and rubella-specific systemic and mucosal immunity | 2 doses | Subcutaneous injection |
| RV1 (Rotarix®) | Live-attenuated rotavirus | Rotavirus-specific mucosal immunity | 2 doses | Oral |
| RV5 (RotaTeq®) | Live-attenuated rotavirus | Rotavirus-specific mucosal immunity | 3 doses | Oral |
- Citation: Miteva D, Peshevska-Sekulovska M, Snegarova V, Batselova H, Alexandrova R, Velikova T. Mucosal COVID-19 vaccines: Risks, benefits and control of the pandemic. World J Virol 2022; 11(5): 221-236
- URL: https://www.wjgnet.com/2220-3249/full/v11/i5/221.htm
- DOI: https://dx.doi.org/10.5501/wjv.v11.i5.221